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Summary 8 
In 2011, there were over 34 million people living with HIV infections, causing a heavy burden 9 
to public health sectors. HIV infection is a life-long threat, which cannot be prevented by 10 
vaccination and cured by antiretroviral drugs. The infected patients rely on daily antiretroviral 11 
therapy to suppress HIV viral replication. Hence, it is important to diagnose HIV infections as 12 
early as possible, and to monitor the efficacy of antiretroviral therapy every 3-6 months. 13 
Different immunoassays detecting HIV antigens and antibodies have been modified to give 14 
better sensitivity and more rapid diagnosis. Several clinical and virological parameters, 15 
including CD4+ cell counts, viral load and drug resistance mutations, are also used for 16 
treatment monitoring. Many molecular assay optimizations are now being imposed to improve 17 
patient care. This review would try to focus on the most updated HIV diagnostic assays, as well 18 
as discussing if there will be upcoming possibilities with other advance technologies. 19 
20 
Introduction 21 
Nearly three decades ago, the human immunodeficiency virus (HIV) was identified to be the 22 
causative agent of the acquired immune deficiency syndrome (AIDS). [1] AIDS progression is 23 
associated with a significant decrease in CD4+ cells, causing failure in the immune systems. 24 
Based on the World Health Organization statistical data, there were over 34 million people 25 
living with HIV infections around the globe till 2011. [201] Great effort has been put into 26 
understanding the functions of different viral proteins and the viral pathogenesis inside 27 
lymphocytes. The research findings allow scientists to discover HIV antigens and antibodies 28 
for detection, antiretroviral drugs for viral inhibition, and vaccines for infection prevention and 29 
transmission.  30 
To maximize the efficacy of patient care in HIV-infected clinics, HIV detection, viral load 31 
measurement and antiretroviral drug resistance monitoring are crucial and can be achieved by a 32 
wide range of laboratory tests. Initially, p24 viral proteins were quantified by an enzyme 33 
immunosorbent assay test. However, the amount of antigen was at limited level during the 34 
stage of acute infection. The assay sensitivity and specificity can be enhanced by the 35 
combination use of antibodies Immunoglobulin G and Immunoglobulin M test. [2] Antibodies 36 
are readily detected after seroconversion, making them the major targets in enzyme immune 37 
assays. Western blot which also detects HIV antibodies, on the other hand, is used as a 38 
confirmation diagnostic test globally. The newly developed nucleic-acid based assays have 39 
shortened the window period from 4 weeks to 2 weeks. [3] However, the molecular testing is 40 
expensive and requires specific diagnostic machines, which is not suitable for the use in remote 41 
settings.  42 
Zidovudine was the first nucleoside reverse transcriptase inhibitor (NRTI) approved by the 43 
Food and Drug Administration (FDA) for HIV treatment since 1987. After a few years of 44 
Zidovudine mono-therapy regimen, cases of drug resistance cases were reported. With protease 45 
inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) sequentially 46 
introduced into the market, the idea of highly active antiretroviral therapy was brought into the 47 
HIV clinics in the mid-1990s. [4] Nowadays, 3 more antiretroviral classes (fusion inhibitors, 48 
CCR5 antagonists and integrase inhibitors) are on the prescription list, covering over 25 single- 49 
or multi-class combinations of antiretroviral drugs.  50 
Under antiretroviral drug suppression, the probability of escape mutation occurrence increases 51 
due to the fact that HIV uses error-prone reverse transcriptase for viral replication.  52 
Consequently, a series of genotypic and phenotypic assays are implemented to deduce drug 53 
susceptibility prior to and during the treatment. Besides, two other clinical parameters, CD4+ 54 
and viral load, are monitored to ensure high treatment efficacy. The CD4+ cell count is treated 55 
as a surrogate marker for observing the strength of the immune system, while the number of 56 
viral copies is used as a prognostic marker for checking viral activity. The effectiveness of HIV 57 
RNA quantitative and qualitative assays have been improved dramatically with molecular 58 
assays. In particular, the latest technology of ultra-deep sequencing further increases the 59 
sensitivity of qualitative assays by sequencing individual amplicons. [5] Determination of the 60 
host genetic polymorphisms has become an extra assessment for antiretroviral drug 61 
prescription due to several adverse effects and metabolic interactions.  62 
HIV is mainly characterized into HIV-1 group M, N, O and HIV-2. The global pandemic is 63 
caused by HIV-1 group M strains while group N and O are very rare. [6] Base on phylogenetic 64 
analysis, group M strains are further categorized into 11 subtypes, 58 circulating recombinant 65 
forms and many unique recombinant forms. [6, 7] [202] HIV-1 subtype B and C infections are 66 
accounted for over 50% of infections worldwide. HIV-2 infections are restricted in the region 67 
of Western Africa and thus limited diagnostic development was done. [6, 8] In this review, we 68 
will focus on HIV-1 and its current diagnostic assays that are newly utilized to facilitate better 69 
detection, shorter turnaround time, and easier to manipulate for diagnosis and antiretroviral 70 
therapy (ART) monitoring.  71 
 72 
HIV-1 detection 73 
HIV-1 can be transmitted vertically by sexual contact, perinatally from mother to child, and 74 
through contaminated blood products and needles. Certain groups of people are at high risk, 75 
including intravenous drug users, blood products recipients, healthcare workers, sexual 76 
workers and the ones who have unprotected sex and multiple partners. HIV-1 treatment is 77 
permanent and expensive. It is therefore important to detect HIV-1 in blood samples and 78 
individuals as early as possible so as to eliminate any possible infection spread.  79 
HIV-1 detection is based on the recognition of viral antigen (p24 antigen test), antibodies 80 
(enzyme-linked immunosorbent assay, ELISA), viral proteins (western blot, WB) and nucleic 81 
acids (nucleic-acid amplification test, NAAT). During acute infection and before 82 
seroconversion, the level of antibodies is very low and only a small amount of detectable 83 
antigen is present. HIV-1 detection is usually less accurate within this one-month window 84 
period. Hence, shortening the turnaround time is always the major hurdle in upgrading the 85 
HIV-1 diagnostic assay. Apart from HIV-1 diagnosis, researchers are interested in identifying 86 
recent infection and the prevalence of infection over time. The amount of antibodies will keep 87 
rising after seroconversion for about 4 months. Using the detuned assays or 88 
sensitive/less-sensitive assays, researchers are able distinguish recent or chronic infections by 89 
discriminating antibodies avidity and titer. [9]  90 
The current diagnostic algorithm relies on rapid antibody tests  or ELISA as a preliminary 91 
screening in blood banks, followed by WB confirmation. A modified algorithm, which can 92 
shorten the turnaround time and strengthen the sensitivity and specificity, was proposed in the 93 
2010 HIV Diagnostics Conference with the devices described in the followings. [10] The 4th 94 
generation ELISA, that can simultaneously detect p24 antigens and both anti-HIV-1 and 95 
anti-HIV-2 antibodies, are now commonly being used in major resource-rich continents. [11-13] 96 
Several FDA-approved or CE-IVD kits are ARCHITECT HIV Ag/Ab Combo assay (Abbott 97 
Diagnostics, Germany), Enzygnost HIV integral II (Siemens Healthcare Diagnostics, 98 
Germany), GS HIV Combo Ag/Ab EIA (Bio-Rad Laboratories,  USA) and VIDAS HIV DUO 99 
Ultra (bioMérieux, France). [14-17] In comparing to the traditional double-confirmed results 100 
by ELISA and WB, the 4th generation immunoassays can detect 84% of acute HIV infection 101 
and are >98% specific and sensitive. [11, 12] They can detect acute infections 7 days earlier 102 
than the 3rd generation ELISA (VITROS anti-HIV 1+2 assay, Ortho-Clinical Diagnostics, UK). 103 
[18] The NAAT-based qualitative assay, (APTIMA HIV-1 RNA Qualitative assay, Gen-Probe 104 
Inc., USA) can further reduce the window period to 26 days before western blot confirmation, 105 
due to the high level of viral replication before immune response establishment. [3, 18, 19] 106 
Rare false-positive results obtained by the NAAT assay had limited its first-line screening 107 
usage in Europe. [20, 21] HIV-1 detection can also be done by rapid tests, which are simple, 108 
faster and can be performed without intensive clinical or laboratory settings. The introduction 109 
of 2nd generation discriminary rapid tests (Multispot HIV-1/HIV-2 rapid test, Bio-Rad 110 
Laboratories, USA) was proven to have comparable results against WB, although 111 
contradictory results were also reported. [22, 23] After evaluating both the pros and cons of 112 
these new technologies, the 4th generation ELISA assays(such as ARCHITECT Ag/Ab combo), 113 
were proposed to be used as the initial screening tool in the US and Europe[10, 21]. Any 114 
positive ELISA results  will further be confirmed by Western Blot or HIV-1/HIV-2 115 
discriminatory assay rapid test. The most sensitive and expensive NAAT tests (e.g. APTIMA) 116 
will only be used as a supplementary verification for any discordant detection.  117 
 118 
Viral load monitoring 119 
HIV-1 infections are considered as a chronic illness, and required non-stop antiretroviral 120 
therapy to suppress viral replication continuously. In order to maintain treatment efficacy, viral 121 
load, CD4+ counts and drug resistance mutations are monitored closely by different laboratory 122 
tests which will be discussed in the followings and summarized in Table 1.  123 
Prior to viral load testing, sample preparation and RNA extraction are both crucial procedures 124 
for proper downstream processing. Blood samples are first collected in EDTA or plasma 125 
preparation tubes (PPT), followed by centrifugation to obtain plasma and/or peripheral blood 126 
mononuclear cells. Due to the instability of virus in specimen, storage under -70℃ are 127 
necessary. Yet the storage condition is impractical in remote-settings and for shipment after 128 
plasma separation. [24] In some resource-limited countries, the use of dried blood spots (DBS) 129 
for sample collection has been proven to be able to keep the viral nucleic acid in good condition 130 
during transportation. The cost of using filter paper for DBS sampling is much more cost 131 
effective than using PPT or EDTA tubes for whole blood collection. [25] Using the Abbott 132 
HIV-1 Real-time assay (Abbott Molecular, USA), the RNA quantitative levels had no 133 
significant difference between freshly separated plasma or with DBS. In a small study cohort, 134 
DBS was 95% sensitive with respect to the real-time assays and the high concordance showed 135 
promising future on sample preparation. [25]  136 
With a good sample collected, the next step would be viral nucleic acid extraction. Viral RNA 137 
extraction requires specialized equipments and sterilized reagents to prevent contaminations 138 
and RNA degradation. The procedure involves protein denaturation, RNA capture on solid 139 
silica surfaces, inhibitors removal and RNA elution from the silica. RNA becomes less stable 140 
after extraction, and requires ultra low temperature storage. Recently, a new device, 141 
RNAStable (Biomatrica, USA), was claimed to be able to stabilize RNA in a dry matrix form 142 
for at least 3 months under room temperature. [26] Apart from it, the trend of RNA extraction 143 
has switched from manual handling to automation in most developed countries. There are 3 144 
commonly used CE-IVD marked automated nucleic acid extraction platforms, the Roche 145 
COBAS AmpliPrep system (Roche Molecular Diagnostics, Germany), the Abbott m2000 146 
system (Abbott Molecular, USA) and the NucliSens easyMAG (bioMérieux, France) in the 147 
market, which can handle a wide range of biological samples with limited hands-on time. [27, 148 
28] These fully automated RNA extraction systems provide standardized extraction protocols, 149 
which is important for extreme low-level vireamia measurement. [29] 150 
The level of plasma HIV-1 RNA can directly reflect the efficacy of HAART, the possibility of 151 
mother-to-child transmission, the odds of drug resistance mutations and the probability of 152 
AIDS progression. [30-32] In clinical definition, a successful ART treatment can inhibit viral 153 
replication and suppress the viral RNA level to ≤50 copies/ml after 24-week treatment. [33] 154 
HIV-1 exists in different genotypes, unique and circulating recombinant forms in isolated 155 
continents. [6] A perfect viral load assay is therefore competent in identifying all the diverse 156 
genotypes and maintaining high sensitivity for substantial patient care. External Quality 157 
Assurance Programs (QCMD, CAP, NATA) are always in place for clinical diagnosis. A 158 
10-year evaluation study (2000-2010) on an external quality assurance program in the United 159 
Kingdom revealed that end-point assays were gradually replaced by real-time assays. [29] In 160 
2010, over 85% of the participating laboratories employed real-time assays for HIV-1 RNA 161 
quantification, which demonstrated the lowest coefficient of variation, most rapid turnaround 162 
time and highest throughout among the other methods.  163 
Currently, there are several CE-IVD marked commercial assays used worldwide, together with 164 
some in-house and research assays. These assays are based on nucleic acid sequence-based 165 
amplification (NASBA), branched-chain DNA assay (bDNA) and reverse transcription 166 
qualitative PCR assay (RT-qPCR). [34, 35] The NucliSENS EasyQ System HIV-1 QT test 167 
(bioMérieux, France) is the only assay using the NASBA technology. NASBA provides rapid 168 
real-time quantification by amplifying RNA with the use of isothermic heat-stable enzymes. 169 
[36] The updated version has allowed better sensitivity towards a range of non-B subtypes. [37] 170 
However, the EasyQ system was showed to have lower specificity and limits of detection 171 
(176 – 3,470,000 copies/mL) than other real-time PCR assays. [35, 38, 39] On the other hand, 172 
the VERSANT HIV-1 RNA 3.0 Assay (Siemens Healthcare Diagnostics, USA) uses the bDNA 173 
technology which relies on signal amplification of specific primer and probes binding to the 174 
HIV-1 pol region. Even though the bDNA assay was demonstrated to give higher diagnostic 175 
sensitivity; it performed poor in low viral load measurements and sometimes under estimated 176 
the viral RNA level in the specimens. [39] Its dynamic range is comparatively narrow, which is 177 
between 75 to 500,000 copies/mL only.  178 
For Roche COBAS Amplicor HIV-1 Monitor Test (Roche Molecular Diagnostics, Germany), 179 
viral RNA was reverse transcribed into complementary double-stranded DNA, followed by 180 
standard PCR. The end-point assay is now gradually replaced by the more sensitive and faster 181 
real-time PCR assays. [29] In turns, the Abbott Real-Time HIV-1 system (Abbott Molecular, 182 
USA) and the COBAS Taqman HIV-1 Test (Roche Molecular Diagnostics, Germany) are the 183 
currently leading technologies for HIV-1 viral load monitoring, with a wider dynamic 184 
diagnostic range of 40 - 10,000,000 copies/mL. [35] Both assays allow automated RNA 185 
extraction and adopting fluorescence-tagged probes targeting HIV-1 pol-int or gag gene 186 
respectively. These real-time assays apparently provide the best sensitivity and specificity on 187 
both B and non-B HIV-1 subtypes. [37]  188 
Unfortunately, real-time quantitative assays are not readily available for resource-limited 189 
settings. The Cavidi ExaVir Load assay (Cavidi AB, Sweden) and the Ultra-Sensitive p24 190 
Antigen Assay (Perkin Elmer Life Sciences, USA) do not require sophisticated laboratory 191 
set-up and provide moderate detection limits for viral load monitoring. The former assay 192 
estimates the reverse transcriptase activity manually while the later assay simply uses the 193 
ELISA approach. [40]  194 
New possibilities are now shown to have lower quantitative limits beyond 50 copies/mL in 195 
real-time assays. The ultrasensitive VERSANT HIV RNA 1.0 assay (kPCR) (Siemens 196 
Healthcare Diagnostic, USA) was used to measure the virological response in a group of 197 
ART-experienced patients. The detection limit could reach 3 copies/mL. [41] However, the 198 
reproducibility of low vireamia is relatively variable by this assay, as well as the 199 
above-mentioned real-time assays by Abbott and Roche. [42] For instance, around 50% of the 200 
blips could not be detected in one of the triplicate tests. Although these commercial tests can 201 
push the limit of detection to ≤20 copies/mL, the reliability and stability remains a concern. It 202 
raised a question whether a single testing is appropriate in the future as biases between different 203 
commercial assays at low-level vireamia may affect treatment guidelines. Two or more 204 
consecutive viral load measurements should be considered to be more conclusive on treatment 205 
monitoring.  206 
There have been controversial debates regarding the impact virologic blips; the persistent of 207 
HIV-1 RNA low vireamia at different categorized viral load copies will increase the chance of 208 
virological failure.[41, 43-46] The existing viruses can escape ART treatment, implying part of 209 
the viral population evolved under drug pressure and become drug resistant mutants. Various 210 
reasons, including ongoing viral replication, methodological variation or emergence of drug 211 
resistant viral particles, may explain the uncertain occurrence of blips. [47] Virological failure 212 
was observed in a significant high proportion of ART-experienced patients with viral load over 213 
3 copies/mL, suggesting an update revision is required for the future treatment guidelines. [41] 214 
The relationship between blips and virological rebound or CD4+ decrease is still under 215 
investigation.  216 
 217 
CD4+ T lymphocyte enumeration 218 
In the last century, CD4+ cell count was used to guide the clinicians on the timing of the 219 
initiation of ART. To balance the benefits of early treatment and the economical burden, CD4+ 220 
cell counts of 500 cells/μL was updated as the standard level for treatment initiation instead of 221 
the previous 350 cells/μL. [48] Large collaborative studies had suggested the initiation of ART 222 
should be as soon as HIV-1 diagnosis regardless of CD4+ cell counts, which can effectively 223 
suppress HIV-1 transmission and AIDS progression. [33, 49] The CD4+ count level is also 224 
useful for treatment efficacy monitoring. Flow cytometry counting with fluorescent-labeled 225 
monocloncal antibodies is the most widely accepted choice in developed countries for 226 
enumeration. The only challenges come from the huge machines and high instrumental cost 227 
which makes it not applicable in resource-limited countries. Manufacturers developed various 228 
point-of-care CD4 testing devices utilizing limited infrastructure, are currently in-use in 229 
remote areas. For instance, the PIMA CD4 Analyzer (Alere, Germany),  the Auto 40 System 230 
(Apogee Flow Systems, UK) and the PointCare NOW system were shown to have results as 231 
good as the traditional flow cytometer. [50-53] The Auto 40 system is as well validated with 232 
reference method and assessed with external quality control. [54] Hence, CD4+ counting 233 
become possible in rural countries for treatment monitoring.  234 
 235 
Drug resistance monitoring (PIs, NRTIs and NNRTIs) 236 
HIV-1 infected patients usually have their viral load and CD4+ counts monitored on a 3-month 237 
to 6-month basis in developed countries.  Virological rebound or treatment failure is defined 238 
whenever the viral load is above 200 copies/mL or within the range of  50 to 200 copies/mL in 239 
two to three consecutive samples after 6 months of antiretroviral therapy. [33, 55] The failing 240 
condition may be due to poor drug adherence, adverse drug effects as well as the emergence of 241 
drug resistance mutants.  [30] During each round of HIV-1 replication, the error-prone reverse 242 
transcriptase increases population dynamics by introducing random mutations into viral 243 
population. Certain proportion of the viruses may become fitter and survive under drug 244 
selective pressure. These viruses, carrying drug resistance mutations, will gradually 245 
accumulate and dominate the major population. Therefore, it is necessary to determine drug 246 
resistance mutations or in turns the drug susceptibility at the moment of virological rebound 247 
before switching treatment regimen.  248 
Phenotypic and genotypic methods are both available commercially for drug resistance 249 
monitoring. Apart from clinical uses, both methods are vital for research and drug 250 
developments. For example, they can be used to deduce the viral resistance and drug inhibitory 251 
mechanisms. Phenotyping estimates the ability of in vitro viral entry or replication under drug 252 
pressure, with respect to a known susceptible reference strain. The in vitro assays require 253 
bio-safety class 3 level laboratory setting to handle infectious tissue cultures, cloning, 254 
transfection and infection. Although phenotypic assays can provide more insights of the virus, 255 
the long turnaround time and expensive running cost restricted the usage to selected clinical 256 
cases only. [56] Genotyping, on the other hand, relies on gene amplification and direct 257 
sequencing, which can provide results within one week. The analysis of nucleic acid sequences 258 
can identify mutations that are established to have known phenotypic drug resistance. [57] 259 
However, genotyping cannot predict drug susceptibility directly and is rather difficult to 260 
interpret if the viral population is complex or super-infected. The basic principle of 261 
phenotyping is to monitor the viral replication and fitness under sequential antiretroviral drug 262 
concentrations. [56] This is achieved by direct isolation of viruses from human plasma or 263 
peripheral blood mononuclear cells, or by generation of a recombinant virus which carries viral 264 
sequences derived from clinical samples and a standard backbone genome. There are two 265 
major commercially available phenotyping tools for examining PIs and NRTIs/NNRTIs 266 
resistance. The PhenoSense HIV assay (Monogram Biosciences, USA) generates resistance 267 
test vectors by inserting the amplified protease (PR) and reverse transcriptase (RT) sequences 268 
into a modified HIV-1 NL4-3 molecular clone lacking PR and RT regions. The products will 269 
then be used to co-transfect human embryonic kidney 293 cell line with a luciferase expression 270 
vector to engineer a pseudotyped virus. The 293 cell line is later infected by the pseudotyped 271 
viruses under different concentrations of the antiretroviral drugs, and produce luciferase 272 
proteins if replication succeeds. Luciferase activity can be measured in a quantification scale, 273 
so as to estimate the drug susceptibility. [58] The AntiVirogram (Virco BVBA, Belgium) is 274 
slightly different from PhenoSense. The recombinant virus generation procedures are similar. 275 
The downstream work relies on culturing the recombinant virus with human T cell line MT4 276 
under all available antiretroviral drugs. No molecular cloning step is involved in this 277 
phenotyping assay and a panel of recombinant strains will be created to reflect the diversified 278 
viral population circulating in the patients. The assay compares the replicating capacity 279 
between the wild-type virus and the constructed virus to provide inhibitory concentration (IC50) 280 
of the antiretroviral drugs. [59] Both assays can readily access the drug susceptibility of patient 281 
with viral load over 500 copies/mL. Although there are no significant differences between the 282 
two assays for PIs and NNRTIs resistances, it seems that the PhenoSense performs better than 283 
the Antivirogram in certain commonly used antiretroviral drugs such as Abacavir, Stavudine 284 
and Didanosine. [60] 285 
In comparing to phenotypic tests, genotypic tests provide a faster turnaround time and simpler 286 
workflow. Current genotypic tests involve direct sequencing of the viral PR and RT region. The 287 
protocols adopted by industries and research laboratories are similar; reverse transcription and 288 
amplification of the RNA extract, followed by population Sanger sequencing. The Trugene 289 
HIV-1 Genotyping Kit (Siemens Healthcare Diagnostics, USA) and the ViroSeq HIV-1 290 
Genotyping System (Celera Diagnostics, USA) are both CE-IVD-marked in Europe and 291 
approved by the FDA in US. [61, 62] Many other commercial genotyping assays, such as 292 
GenoSure MG (Monogram, USA), and less-pricey in-house genotyping assays are also well 293 
evaluated worldwide. [63-66] The major limitation of both widely validated kits is that they 294 
were designed basing on the HIV-1 subtype B viral genome, whereas their performance on 295 
HIV-2 or other HIV-1 genoptypes remains uncertain. A recent study showed that the 296 
sequencing primers of the ViroSeq system failed to sequence a panel of diverse subtypes. [67] 297 
In particular, 1 out of the 7 sequencing primers failed to sequence over 50% of the included 298 
non-B subtype samples. Since non-B subtype HIV-1 are the predominant circulating strains in 299 
Asia, Africa and some parts of the European continents [6], the high failure rate of the ViroSeq 300 
system on non-B viruses would be a major challenge in the future. It is believed that a modified 301 
version of primers will be released in order to provide better coverage to a wide range of 302 
genotypes identified recently. Independent laboratories have established various in-house 303 
genotyping targeting non-B subtypes, including subtypes A, C, D, CRF01_AE, CRF02_AG. 304 
The in-house assays have low sequencing failure rate and are able to achieve over 95% 305 
sensitivities and specificities against validated kits. [64, 68, 69] In combining the advantages of 306 
both genotyping and phenotyping, A third hybrid approach, the VircoTYPE HIV-1 (Virco 307 
BVBA, Beerse, Belgium), is comprised of genotyping technique but with phenotypic analysis. 308 
It is a modified version of VirtualPhenotype-LM and uses a linear regression modeling with 309 
over 80,000 pairs of correlated genotypic and phenotypic samples for accurate drug 310 
susceptibility prediction. [59] This approach provides a third option for drug resistance 311 
monitoring by obtaining phenotypic information from genotyping only 312 
The interpretation of the genetic sequences relies heavily on the most updated knowledge of 313 
correlation between mutations and in vitro drug susceptibility. There are several HIV-1 drug 314 
resistance algorithms available in the Internet, including the Stanford HIV db Program 315 
(http://hivdb.stanford.edu/) (Stanford University, USA) and the ANRS database 316 
http://www.hivfrenchresistance.org) (Agence Nationale de Recherches sur le Sida, Paris, 317 
France). [70, 71] The former database allows the input of a single PR/RT mutation or the 318 
PR/RT sequence for drug resistance interpretation on 19 commonly prescribed PR and RT 319 
inhibitors while the later provides tables of rules for each class of drug resistance. Moreover, 320 
genotypic sequences rely heavily on manual proof-reading and interpretation to the occurrence 321 
of mixed viral population or poor sequence quality. This requires several hours of training for a 322 
new technical staff and it is difficult to standardize their interpretation level among laboratories. 323 
A new automated sequence analysis tool, RECall (http://pssm.cfenet.ubc.ca), does not require 324 
manual editing and can identify mixed genetic population has been developed recently. [72] 325 
This analysis tool shared over 99% of sequence agreement in comparing to manual editing and 326 
will be a solution to tackle to standardization problem mentioned.  327 
 328 
Drug resistance monitoring (Integrase and fusion inhibitors) 329 
Integrase inhibitors (INI) and fusion inhibitors are the 2 recently FDA-approved antiretroviral 330 
drug classes. INI has a relatively low genetic barrier, and more expensive than PIs and 331 
NRTIs/NNRTIs. It is only used for patients who had developed multi-classes drug resistant or 332 
low tolerance of adverse effects. [33] Drug resistance monitoring is available for INI 333 
commercially, yet none of them were approved by the US FDA and CE-IVD marked. The basic 334 
principles of genotyping and phenotyping for INI and fusion inhibitors are similar to those of 335 
the PIs and RTIs classes. The PhenoSense and GeneSeq Integrase assays (Monogram, USA) 336 
are the more commonly used commercially available phenotyping and genotyping assay 337 
respectively. [73] Limited evaluation was carried on the ViroSeq and Trugene systems on their 338 
capability of integrase drug resistance interpretation. [74, 75] The testing on fusion inhibitor is 339 
further limited, which is mainly due to the inconvenient injections of fusion inhibitor. 340 
Moreover, natural occurring drug resistance is found in certain HIV-1 subtypes, restricting the 341 
susceptibility of this class. [76-78]  342 
 343 
Tropism identification and drug resistance monitoring (CCR5 antagonist) 344 
HIV-1 tropism is defined by the ability of virus infection with the two major chemokine 345 
co-receptors, CCR5 and CXCR4. [79] R5-tropic (R5) virus is previously thought to be the 346 
prevalent strain during transmission, while X4-tropic (X4) virus emerges due to AIDS 347 
progression at a later disease stage. [80, 81] Recent controversial studies observed a higher 348 
percentage of X4 virus in treatment-naïve patients of some subtypes and identified 349 
transmission cluster consisted of X4 virus only. [81-83] The transition phase in the viral 350 
population implies the possibility of a mixture of R5 and X4 viruses. The importance of 351 
tropism identification is growing, due to the first introduction of CCR5 antagonist into salvage 352 
therapy in 2007. Treatment guidelines in Europe and USA strongly recommend tropism tests 353 
must be done prior to initiation of CCR5 antagonist, as it only suppresses R5 viral entry. [33, 55, 354 
84]  355 
The successfulness of CCR5 antagonist represents a new antiretrovirals era for scientists. The 356 
mechanism seems to be simpler than the traditional drug classes, although the side effects of 357 
blocking such co-receptor remain a concern in normal human metabolism. The phenotypic and 358 
genotypic tropism tests are therefore aggressively being developed in this decade.  359 
The MT-2 assay is the most traditional phenotypic tropism assay. Viruses isolated from patients 360 
are used to co-culture with human T cell line MT-2, which express CXCR4 coreceptors only. 361 
Syncytia will be formed if the viral isolates are able to infect MT-2 cells, implying the presence 362 
of X4- or mixed/dual-tropic (D/M) viruses. [85] The use of MT-2 assay is limited, as it requires 363 
specialized laboratory set up and fresh samples for virus isolation. Apart from it, it is 364 
impossible to distinguish between virus isolation failure and a pure R5 virus population, due to 365 
the lack of a CCR5 coreceptor-expression cell line. To overcome the limitations in MT-2 assay, 366 
other single-cycle recombinant virus assays are as well applicable in tropism phenotypic tests. 367 
[86] The Enhanced Sensitivity Trofile Assay (ESTA) (Monogram Biosciences, USA) is the 368 
current ‘gold standard’ assay that has been clinically validated the most. [87, 88] The amplified 369 
env gene is inserted into an expression vector, followed by co-transfecting 293 cell lines with a 370 
luciferase-expression vector. Quantification can be done by measuring the luciferase signal 371 
after a single round of infection of human primary glioblastoma U87 cell lines, with or without 372 
appropriate antagonists. The assay requires at least 1000 copies/ml of viral load to perform and 373 
3 ml of fresh sample or frozen plasma that are stored in less than 3 months. As X4 virus usually 374 
exists as a minority, the detection limit of ESTA has now being improved greatly from the 375 
previous 10% to 0.3% of the total population and is 100% sensitive. [89] The Toulouse 376 
Tropism Test (INSERM, France) uses similar approach but with different backbone vector. 377 
Both phenotypic tests are highly concordant except the fact that the ESTA assay is more 378 
sensitive. [90]  379 
Tropism determination can also be done by genotyping the third variable (V3) loop of HIV-1 380 
env gene. [84, 91, 92] The 35-amino acids region is believed to bind and interact with the 381 
co-receptor. The genotypic interpretation is originally based on the net charge and basic amino 382 
acids at position 11 and/ 25 of the sequences. [93] Two more advance bioinformatic algorithms, 383 
such as Geno2Pheno [co-receptor] (G2P) 1.2 384 
(http://coreceptor.bioinf.mpi-inf.mpg.de/index.php) and Web PSSM 385 
(http://indra.mullins.microbiol.washington.edu/webpssm), are publicly available and provide 386 
instant tropism predictions by V3 nucleotides or amino acids sequences respectively. [94, 95] 387 
G2P relies on the support vector machine technology trained with a large database of 388 
nucleotide sequences and corresponding phenotypes. The interpretation is given in the form of 389 
false positive rate, defining the likelihood of mistakenly classifying an R5 virus as X4 instead. 390 
Different cut-offs and clinical parameters can be chosen in G2P, depending on the patients’ 391 
treatment history and the amplification results. [84] Web PSSM is slightly different, as it takes 392 
into account of every amino acid at every position, but not insertions and deletions, to 393 
determine the probability of an X4 virus. The interpretation is more complex when there is a 394 
mixed base pair positions and generate more than one answer, which make it less convenient 395 
for clinical practice and evaluation. Many clinical studies had reported a good correlation 396 
between Trofile and G2P genotyping data in subtypes B and C. [96, 97] Triplicate V3 397 
sequencing is currently recommended, which may have a better chance of detecting the 398 
low-level of X4 minority. [98]  399 
Several limitations are observed in V3 genotyping. Some heavily-treated patients usually have 400 
a mixed viral population in their samples, which creates complication during direct sequencing. 401 
Population sequencing detects up to 20% of the minority, which means 20% of the hidden X4 402 
virus can grow and dominate under a short period of CCR5 antagonist suppression. New 403 
technologies were developed recently to overcome these disadvantages. The denaturing 404 
heteroduplex tracking assay (HTA) can detect as low as 0.5% minority strains, which is more 405 
sensitive than Sanger sequencing. [99, 100] R5 and X4 viruses may only differ in a single 406 
amino acid substitution. Therefore the HTA adopts various techniques to enhance the 407 
sensitivity and specificity. The V3 region is first amplified with locked nucleic acids 408 
incorporated primers, and annealed by a single-stranded fluorescent probe. The probe consists 409 
of V3 R5 consensus so that X4 samples can form heterodupluxes with the probe. A 410 
denaturing-gel-electrophoresis can distinguish the variants as DNA homodupluxes migrate 411 
faster than DNA heterodupluxes, whose conformation can be, strengthen by formamide. Viral 412 
tropic is therefore determined by the migration distance on the gel, and the study successfully 413 
detected viral quasispecies in over 50 clones. This technique opens a new door for molecular 414 
diagnosis in quantitative analysis and possible automation by the capillary electrophoresis 415 
system, another upcoming trend.  416 
 417 
Ultra-deep pyrosequencing 418 
Direct sequencing is only capable of detecting roughly 20% of the minor viral population, 419 
triggering more advance research to lower this detection limit. Ultra-deep pyrosequencing 420 
(UDS) technique, provided by the Genome Sequencer FLX (GS-FLX) and Junior (GS-Junior) 421 
systems (Roche-454 Life Sciences, Germany), has been developed to enhance the throughput 422 
and sensitivity for sequencing. The systems first generate a library by amplifying the target 423 
genes with specific fusion primer. Each library fragment will be attached to one bead, followed 424 
by emulsifying in a water-in-oil mixture inside microreactors. Emulsion PCR amplification 425 
creates millions of fragment copies which are then loaded onto the PicoTiterPlate device for 426 
pyrosequencing. [5, 101] The latest version can achieve up to 700 megabases throughputs 427 
within 23 hours with read length of 1,000 basepairs.  428 
UDS has been extensively evaluated in HIV-1 diagnostic fields. Both pros and cons were 429 
reported from many clinical studies. First of all, the cost of running UDS is largely higher than 430 
population sequencing and is not as easy accessible as direct sequencing. More importantly, the 431 
error rate of UDS is very high comparing to direct sequencing. In turn, the high throughput is 432 
the major overwhelming advantage of UDS. Several PIs and RTIs resistance monitoring was 433 
carried by UDS lately. [102-104] It seems that UDS is more applicable to 434 
treatment-experienced patients, yet more studies are required to support the use of UDS in 435 
clinical settings. Besides, the clinical response between the quasispecies and routine Sanger 436 
sequences was similar in a recent study. Any extra viral variants observed in quasispecies 437 
might actually do not exist in the population nor had loss of replicating ability. [102] Although 438 
the study was of a small group of patients, it pointed out that the new technology may not have 439 
many implications on clinical evaluation. Moreover, the large amount of data produced in UDS 440 
may require a more delicate and detailed database for analysis. Another retrospective study 441 
was conducted to show that UDS could predict the virological response more accurate than the 442 
triplicate tropism sequencing approach. [105] It included patients enrolled in MOTIVATE and 443 
A4001029 studies who were Maraviroc-experienced. Triplicate population sequencing was not 444 
able to accurately predict all X4-tropic infections. Any R5 predictions was further deep 445 
sequenced by GS-Junior or GS-FLX system, which have a sensitivity of 0.5% detection limit. 446 
A significant number of patients who were classified in R5 infection were re-grouped into D/M 447 
by UDS. The correlation between Maraviroc-responders from MOTIVATE and A4001029 448 
studies was improved. The study showed that the tropism determined by UDS and ESTA were 449 
similar, suggesting UDS can potentially replace the necessity of phenotypic assay, and mark it 450 
as gold standard instead. The potential of replacing traditional Sanger sequencing by UDS in 451 
patient care require further evaluation on the cost and practicality.  452 
 453 
Host genetics polymorphisms 454 
The close interaction and relationship between virus, antiretroviral drugs and the host cannot 455 
be underestimated. It is because a few single nucleotide polymorphisms (SNPs) as well as 456 
human leukocyte antigen (HLA) typing are linked to clinical failure or hypersensitivity 457 
symptoms in HIV-1 patients. Therefore, understanding the link between pharmacogenomics 458 
and metabolism is crucial. The most important example is demonstrated in CCR5 459 
polymorphisms. CCR5-△32 has a 32-base deletion in CCR5 genes that will result in truncated 460 
malfunctioned protein. CCR5-△32 homozygotes are naturally resistant to R5 infections and 461 
heterozygotes are expected to have a slower disease progression than normal. [106] In 462 
determining the host status of CCR5 gene, it helps clinicians to have a better idea on the 463 
frequency of treatment monitoring. A meta-analysis included over 12,000 genotyped study 464 
objects to evaluate the importance of CCR5-△32 heterozygosity. [107] There were no 465 
consistent research outcome currently available, as contradicted predictions on the protective 466 
behavior of CCR5-△ 32 remains unclear. The CCR5 level expressed in CCR5-△ 32 467 
heterozygotes can possibly be as high as normal, and the expression level can be affected by 468 
other factors apart from genotype.  469 
Concerning the relationship of host genetic and drug hypersensitivity, HLA-B*5701 and 470 
Abacavir is a well defined example. [108] Abacavir is widely prescribed as the first line 471 
treatment regimen. Clinicians observed patients on Abacavir developed serious side effects, 472 
such as rash, fever, and these effects disappeared after discontinuing Abacavir treatment. Later 473 
it was found that if patients carrying HLA genoptype B*5701 in their alleles, they will have 474 
hypersensitivity reaction towards Abacavir. [109] The prevalence of HLA-B*5701 varies 475 
greatly around the world, ranging from 8-10% in Caucasians and Thai, to 1 % in Africans, and 476 
to nearly 0% in Japanese, Taiwanese and Korean. [110-113] The treatment guidelines indicated 477 
that the screening of HLA-B*5701 is compulsory before Abacavir prescription. There are 478 
many FDA-approved HLA typing kits, which mostly utilize the direct sequencing techniques 479 
or make use of the specific oligonucleotide probes hybridization after PCR. [114, 115] Other 480 
SNPs were shown to have association with severe kidney tubular dysfunction in 481 
Tenofovir-experienced patients. [116] Tenofovir is a popular first-line NRTI for treating HIV-1 482 
infection with tolerable side effects usually. [117] The renal clearance of Tenofovir involves 483 
multidrug-resistance protein 2 and 4, which are encoded by the adenosine triphosphate-binding 484 
cassette genes ABCC2 and ABCC4. [118, 119] Using the TaqMan SNP Genotyping Assays 485 
(Applied Biosystems, CA, USA) two SNPs of the ABCC2 gene were identified. The CC 486 
genotype at position -24 and AA genotype at position 1249, were shown to have strong 487 
association with kidney tubular dysfunction in Japanese and European population. [120, 121].  488 
The highly polymorphic hepatic cytochrome P450 isoenzyme 2B6 (CYP2B6) gene 489 
demonstrates the last example of host genetic polymorphisms. This gene participates in many 490 
antiretroviral drugs metabolism, Efavirenz and Nevirapine in particular. [122] A SNP at 491 
position 516 that changes from guanine to thymidine on the CYP2B6, is widely reported to 492 
affect Efavirenz and Nevirapine concentration in plasma. [123] Direct sequencing can detect 493 
the SNPs easily, supplemented by pharmacokinetic studies to monitor the concentration of 494 
antriretroviral drugs in plasma. A new finding on the high Efavirenz level in hair, measured by 495 
liquid chromatorgraphy coupled with tandem mass spectrometry, provides more insights on 496 
alternative detection methods. [124, 125] The abovementioned examples elucidated the vital 497 
host genetic determinants affecting antiretroviral prescription preferences, together with the 498 
evidence on dissimilar disease progression. The cost of patient care after specific genes made 499 
known to the adverse side effects. Nonetheless, larger study cohorts are required to reveal the 500 
inconsistency in various SNPs and host reactions on virus and antiretroviral drugs.   501 
 502 
Conclusions & Future Perspectives 503 
After nearly three decades of the discovery of AIDS and HIV viruses, clinicians and scientists 504 
have gone through many hurdles in unmasking the mystery of this virus. Current diagnostic 505 
assays can detect both HIV antigens and antibodies, providing more rapid and faster detection 506 
than before. Viral load and CD4 measurements are crucial for treatment monitoring. Lowering 507 
the detection limit to possibly 20 copies/mL in viral load assays, the clinicians are able to 508 
identify treatment failure patients at the earliest stage. HIV-1 genotyping is widely accepted as 509 
the pre-dominant test to identify drug resistance mutations and tropism, although rare cases 510 
require phenotyping tools for detailed analysis.  511 
It is not surprised that the detection limits, sensitivity and specificity, costing and turnaround 512 
time of all molecular assays will be improved this century with the introduction of new ideas 513 
like ultra-deep sequencing and nano-particles assays.[126] Amplicons sequencing allow 514 
researchers to identify individual viral mutants that previously undetected in population 515 
sequencing. However this technique is highly demanded in budgeting and infrastructure 516 
settings, and generates a large amount of data which requires highly-trained technicians and 517 
complicated softwares to analyze. Various constraints at resource-limited or point-of-care 518 
settings will as well be eliminated with portable devices with lower cost.   519 
520 
Executive Summary 521 
HIV-1 detection 522 
 HIV-1 diagnostic assays include p24 antigen test, enzyme-linked immunosorbent assays 523 
(ELISA), western blot (WB) and nucleic-acid amplification test (NAAT). 524 
 The 4th generation of ELISA and newly developed NAAT could successfully detect HIV 525 
antigens and antibodies around 20 days earlier than WB confirmation. 526 
Viral load monitoring 527 
 Plasma preparation tubes and EDTA tubes are used for sample collection in developed 528 
countries, while dried blood spots are used in rural areas.  529 
 RNA extraction is largely facilitated by automated systems to reduce hands-on time and 530 
provide standardized protocols.  531 
 Traditional reverse transcriptase polymerase chain reactions are mostly replaced by 532 
real-time assays such as nucleic acid sequence-based amplification and branched-chain 533 
DNA assay. 534 
 Low vireamia measurement, which may affect treatment guidelines, varies in between 535 
assays and laboratories, and requires further evaluation. 536 
CD4+ T lymophocyte enumeration 537 
 Flow cytometry counting is implemented in developed countries while mobile flow 538 
cytometers provide alternative measurements in rural countries. 539 
Drug resistance monitoring (PIs, NRTIs and NNRTIs) 540 
 When a patient experiences virological rebound or CD4+ decline, viral phenotyping and 541 
genotyping is required to estimate drug susceptibility and resistance. 542 
 Phenotyping relies on the cloning of protease and reverse transcriptase sequences into a 543 
modified vector, which can be transfected into human embryonic kidney cell line. 544 
Luciferase signals are generated when the pseudotyped virus manage to infect the cell line 545 
again or co-culture with human T cell line and replicate under different concentrations.  546 
 Genotyping bases on direct sequencing of protease and reverse transcriptase regions and 547 
analyzed by commercial phenotyping database or various open-assessed algorithms on 548 
internet.  549 
Drug resistance monitoring (Integrase and fusion inhibitors) 550 
 Phenotyping and genotyping assays are similar to those for PIs, NRTIs and NNRTIs.  551 
 Due to the less common use of integrase and fusion inhibitors, limited clinical validation 552 
is available.  553 
Tropism identification and drug resistance monitoring (CCR5 antagonist) 554 
 HIV-1 virus utilizes CCR5 and/or CXCR4 co-receptor for viral entry. It is compulsory to 555 
identify viral tropism before the use of CCR5 antagonist. 556 
 Viral tropism can be determined by phenotyping and genotyping, with similar principles 557 
in pol gene. 558 
 Currently, no known CCR5 antagonist drug resistance mutations are identified.  559 
Ultra-deep pyrosequencing 560 
 In comparing to Sanger sequencing, ultra-deep pyrosequencing can detect up to 0.5% of 561 
minor variants in viral population. 562 
 Clinical studies demonstrated better treatment guidelines by ultra-deep pyrosequencing. 563 
 However, the machines and running costs are extremely high that restrict the possibility of 564 
routine monitoring in viral load, drug resistance mutations and tropism identification.  565 
Host genetics polymorphisms 566 
 A few single nucleotide polymorphisms and human leukocyte antigen (HLA) typing were 567 
shown to have clinical relevance on treatment failure and hypersensitivity reactions in 568 
HIV-1 patients.  569 
 Examples of CCR5-∆32, HLA-B*5701, ABCC2 gene and CYP2B6 are discussed. 570 
571 
Table 1. Summary of current diagnostic assays 572 
 Current 
Technology Target Sites Most Common Assays 
Manu- 
facturers Detection Limits Ref. 
H
IV
-1
 D
et
ec
tio
n 
ELISA (4th 
generation) 
HIV-1 & HIV-2 Ab & 
p24 Ag 
ARCHITECT HIV Ag/Ab 
Combo assay* Abbott  
p24: < 50 pg/mL  
Ab: 100% Sensitive 
20 days before WB +ve 
10-14 
HIV-1 gp41, HIV-2 
gp36 Ab & HIV-1 p24 
Ag 
Enzygnost HIV Integral II Siemens 
p24: >100 pg/mL 
Ab: 100% Sensitive 
14 days before WB +ve 
HIV-1 gp160, HIV-2 
gp36 Ab & p24 Ag VIDAS HIV DUO Ultra bioMérieux 
p24: >3 pg/mL 
Ab: >98% Sensitive 
20 days before WB +ve 
HIV-1 gp160, HIV-2 
env Ab & HIV-1 p24 
Ag 
GS HIV Combo Ag/Ab 
EIA* Bio-Rad 
p24: < 50 pg/mL 
Ab: 100% Sensitive 
19 days before WB +ve 
NAAT RNA APTIMA HIV-1 RNA Qualitative* Gen-Probe 
RNA: >14 cp/mL 
95% Sensitive  
26 days before WB +ve 
16 
V
ir
al
 L
oa
d 
M
on
ito
ri
ng
 
RT-qPCR RNA gag & LTR region COBAS Tagman HIV-1* Roche 48 – 10,000,000 cp/mL 
31, 33 
RNA pol Abbott Real-time HIV-1* Abbott 40 – 10,000,000 cp/mL 
NASBA RNA gag NucliSENS EasyQ system HIV-1 QT* bioMérieux 176 – 3,470,000 cp/mL 
31-34 
bDNA RNA gag Versant HIV-1 RNA 3.0 *  Siemens 75 – 500,000 cp/mL 35 
RT-kPCR RNA pol/int Versant HIV RNA 1.0 Siemens 37 – 11,000,000 cp/mL 37 
D
ru
g 
R
es
ist
an
ce
 
M
on
ito
ri
ng
 
Phenotyping 
(cloning, 
transfection 
&infection) 
RNA pol  
(PR & RT) 
Phenosense Monogram ≥ 500 cp/mL 53 
Antivirogram  Virco ≥ 500 cp/mL 54 
RNA pol  
(INT) Phenosense Integrase Monogram 
Limited information 
available 
66 
Genotyping 
(direct 
sequencing) 
RNA pol 
(PR & RT) 
Trugene* Siemens ≥1,000 cp/mL 56 
Viroseq* Celera 2,000 – 750,000 cp/mL 57 
RNA pol  
(INT) 
GeneSeq Integrase Monogram Limited information 
available 
66 
ViroSeq Integrase Celera 67 
Tr
op
is
m
 
D
et
er
m
in
at
io
n Phenotyping 
(cloning, 
transfection 
& infection) 
RNA env  
(gp160) 
Enhanced Sensitivity 
Trofile Assay Monogram 
100% Sensitive at 0.3% 
CXCR4, ≥1,000 cp/mL 
82 
RNA env  
(gp120 & gp41) Toulouse INSERM 
100% Sensitive at 0.5% 
CXCR4, ≥1,000 cp/mL 
83 
Genotyping 
(direct 
sequencing) 
RNA env  
(V3 loop) In-house only ---- ----- 
77, 84, 
85 
Abbreviations: * - FDA approved assays; ELISA – Enzyme-Linked Immunosorbent Assay; NAAT – Nucleic Acid 573 
Amplification Test; WB – Western Blot; RT-qPCR – Reverse Transcriptase – qualitative Polymerase Chain 574 
Reaction; NASBA – Nucleic Acid Sequence-Based Amplification; Ab – Antibodies; Ag – Antigens; bDNA – 575 
Branched-chain DNA assay; RT-kPCR – Reverse Transcriptase – kinetic Polymerase Chain Reaction; cp/mL – 576 
copies/mL; +ve – positive; LTR – Long-Terminal Repeats; PR – protease; RT – Reverse Transcriptase; INT - 577 
Integrase 578 
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